The PR released on January 13 relates specifically to ABL synergy with SGLT2s and DPP4s.  The PR yesterday also specifically references the BT status for ABL in the same vein, synergy with top SOC with high-intensity statins.  So, is it now a stretch to see a deal (partnership) with both manufacturers of SGLT2s and DPP4s (EL/BI & Merck respectively) which would then provide the $$$ means for RVX to continue pursuing the development of ABL for CKD and VD?  These two PRs back to back is no coincidence.  It would also then still leave RVX with the freedom to sell the company lock, stock and barrel to any BP.  Sounds logical to me.